Short-term clinical remission rates and adverse reactions of rituximab compared to cyclosporine in patients with refractory membranous nephropathy (MN)
{{output}}
Objective: To compare short-term remission rates, adverse events, and laboratory trends between rituximab (RTX) and cyclosporine A (CsA) in refractory membranous nephropathy (MN), and to identify independent predictors of 12-mont... ...
